^
    Apply
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer (NCT05101564)
    Phase 2
    Stanford University
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    03/20/2023
    Primary completion :
    09/01/2025
    Completion :
    12/01/2026
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative
    |
    Piqray (alpelisib) • fulvestrant • Truseltiq (infigratinib) • letrozole • zotatifin (eFT226) • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)
    Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3) (NCT04059484)
    Phase 2
    Sanofi
    Active, not recruiting
    Last update posted :
    04/24/2024
    Initiation :
    10/22/2019
    Primary completion :
    02/15/2022
    Completion :
    09/30/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • amcenestrant (SAR439859)
    Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1) (NCT03284957)
    Phase 1/2
    Sanofi
    Active, not recruiting
    Last update posted :
    02/12/2024
    Initiation :
    09/20/2017
    Primary completion :
    12/29/2027
    Completion :
    12/29/2027
    HER-2 • ER
    |
    Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • amcenestrant (SAR439859) • midazolam hydrochloride
    Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2) (NCT03816839)
    Phase 1
    Sanofi
    Active, not recruiting
    Last update posted :
    12/28/2023
    Initiation :
    03/25/2019
    Primary completion :
    10/27/2020
    Completion :
    11/29/2024
    HER-2 • ER
    |
    amcenestrant (SAR439859)